FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

AIMode News Desk · curated summary

August 14, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class STAT

About this story

This story was aggregated from STAT. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

For agents:JSON record OpenAPI WebMCP llms.txt

More in Health

Health

FDA Approves Iberdomide Combo for Relapsed or Refractory Multiple Myeloma

Related coverage: FDA Approves Iberdomide Combo for Relapsed or Refractory Multiple Myeloma Medscape

Medscape · 2 hours ago

Health

NEWSLETTER: Experimental blood test finds high-risk colorectal lesions before cancer develops

Related coverage: NEWSLETTER: Experimental blood test finds high-risk colorectal lesions before cancer develops Reuters

Reuters · 2 hours ago

Health

Cancer research needs sustainable funding from New Jersey, advocates say

Related coverage: Cancer research needs sustainable funding from New Jersey, advocates say New Jersey Monitor

New Jersey Monitor · 2 hours ago

Health

‘Super movers’ are speed walking their way to better brain health

Related coverage: ‘Super movers’ are speed walking their way to better brain health CNN Column | Why ‘super movers’ have healthier brains — and how to be one The Washington Post Fast walkers in their eighties linked to lower dementia risk The Times Rodrigo Arteaga, doctor: four benefits of walking that nobody tells you about, and the one for your brain arrives first OkDiario How Much Movement Does Your Aging Brain Really Need? MindBodyGreen

CNN · 2 hours ago